A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Molecular Cancer Therapeutics
B-cell maturation antigen (BCMA) is expressed on normal and malignant plasma cells and represents a potential target for therapeutic intervention. BCMA binds to two ligands that promote tumor cell survival, a proliferation inducing ligand (APRIL) and B-cell activating factor. To selectively target BCMA for plasma cell malignancies, we developed antibodies with ligand blocking activity that could promote cytotoxicity of multiple myeloma (MM) cell lines as naked antibodies or as antibody-drugdoi:10.1158/1535-7163.mct-07-0464 pmid:18025285 fatcat:h6uthj7ynjdphjzea6bwt7uwnu